Fig. 4

AMPAkine in the NAc core occludes the anti-aversive effect of PL on chronic inflammatory pain. a Schematic of the CPP test for tonic-aversive response in CFA-treated rats after AMPAkine or saline infusion in the NAc core. One of the chambers was paired with PL activation; the other chamber was not. No peripheral stimulus was given. b Saline-infused rats that received ChR2 injection preferred the chamber associated with PL activation. n = 6, *p = 0.0237, paired Student’s t-test. c Saline-infused rats that received YFP injection showed no preference for light treatment. n = 6, p = 0.5973, paired Student’s t-test. d CPP score for PL activation in the presence of spontaneous or tonic pain. n = 6, *p = 0.0232, unpaired Student’s t test. e AMPAkine pretreatment occluded the anti-aversive effects of PL activation. Rats which received CX546 infusion in the NAc core prior to CPP test did not demonstrate a preference for the chamber associated with PL activation. n = 6, p = 0.4405, paired Student’s t-test. f AMPAkine-infused rats which received YFP injection showed no chamber preference. n = 6, p = 0.1278, paired Student’s t-test. g AMPAkine pretreatment occluded the anti-aversive effects of PL activation in CFA-treated rats. After AMPAkine infusion into NAc core, the CPP score for PL activation was not increased compared with YFP control. n = 6, p = 0.6102, unpaired Student’s t test. h Compared with saline, AMPAkine treatment prior to CPP test occluded the anti-aversive effects of PL activation in CFA-treated rats. n = 6, *p = 0.0294, unpaired Student’s t test